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Abstract
Cisplatin is widely used as an antineoplastic drug, but its ototoxic and nephrotoxic side-effects, as well as the inherent or
acquired resistance of some cancers to cisplatin, remain significant clinical problems. Cisplatin’s selectivity in killing rapidly
proliferating cancer cells is largely dependent on covalent binding to DNA via cisplatin’s chloride sites that had been
aquated. We hypothesized that cisplatin’s toxicity in slowly proliferating or terminally differentiated cells is primarily due to
drug-protein interactions, instead of drug-DNA binding. To identify proteins that bind to cisplatin, we synthesized two
different platinum-agarose conjugates, one with two amino groups and another with two chlorides attached to platinum
that are available for protein binding, and conducted pull-down assays using cochlear and kidney cells. Mass spectrometric
analysis on protein bands after gel electrophoresis and Coomassie blue staining identified several proteins, including
myosin IIA, glucose-regulated protein 94 (GRP94), heat shock protein 90 (HSP90), calreticulin, valosin containing protein
(VCP), and ribosomal protein L5, as cisplatin-binding proteins. Future studies on the interaction of these proteins with
cisplatin will elucidate whether these drug-protein interactions are involved in ototoxicity and nephrotoxicity, or contribute
to tumor sensitivity or resistance to cisplatin treatment.
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Introduction
Cisplatin (cis-diamminedichloroplatinum[II]) is widely used in
chemotherapy to treat various cancers with high efficacy, with
remission rates of over 90% in testicular cancers [1]. More than
one million patients receive platinum agents in North America and
Europe each year. However, cisplatin therapy is limited by
intrinsic and acquired tumor resistance, and severe side-effects in
specific tissues [2]. Over 60% of cisplatin-treated pediatric patients
develop irreversible hearing loss [3,4], and more than 70%
experience acute renal dysfunction [5]. Pediatric hearing loss
delays language acquisition, educational attainment and social
integration [3,6].
Cisplatin induces DNA damage and cell death in rapidly-
proliferating cells, especially cancer cells. This involves aquation of
the two chlorides (Fig. 1), and subsequent binding to DNA,
forming DNA adducts [7–9]. Cells recognize this as DNA damage,
and induce various signaling cascades, leading to cell cycle arrest,
apoptosis, or DNA repair [10]. However, kidney proximal tubule
cells and cochlear cells have low rates of cell proliferation (or none
in the case of post-natal cochlear hair cells), yet these cells are
especially prone to cisplatin-induced cytotoxicity. Oxidative stress
induced by cisplatin has been suggested as a major factor in
ototoxicity and nephrotoxicity [11–13]. This also involves the
conversion of cisplatin into highly-reactive aquated forms that
rapidly bind to thiol-containing antioxidants, including glutathione
[14]. Cisplatin interaction with antioxidants leads to the accumu-
lation of endogenous reactive oxygen species, which in turn act on
many targets in the cell, including lipids, proteins, and DNA,
inducing cytotoxicity. Several anti-oxidants including D-methio-
nine, N-acetylcysteine, and sodium thiosulphate can prevent
platinum-induced ototoxicity [15–17].
Carboplatin (Fig. 1), a less toxic analog of cisplatin that is used
for some types of cancer, does not readily form platinum-DNA
adducts in the cochlea and kidney [18], because its six-membered
ring confers greater chemical stability, reducing its conversion rate
to aquated platinum species [19]. Although carboplatin is less
ototoxic and nephrotoxic compared to cisplatin, carboplatin-
induced cytotoxicity still occurs, and unwanted side-effects remain
problematic at the doses required for clinical efficacy [20,21]. It is
possible that these side-effects are caused by non-oxidative stress
mechanisms because of the greater chemical stability in carbo-
platin compared to cisplatin.
Since both cisplatin and carboplatin have two amino groups
attached to platinum (Fig. 1), these drugs could induce cytotoxicity
through molecular interactions at the amino groups. We
hypothesized that there are proteins that specifically bind to these
two amino groups. This drug-protein interaction could induce
toxicity, and trigger cell death mechanisms. In this study, we
synthesized two different platinum complexes, one with two amino
groups and the other with two chlorides covalently coordinated to
platinum and available for protein binding. We conducted protein
pull-down assays using agarose conjugates of these complexes, and
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identified the proteins that bind to cisplatin at the amino groups by
mass spectrometric analysis.
Materials and Methods
Synthesis of Pt complexes and their agarose conjugates
General. Unless otherwise indicated, all commercially avail-
able starting materials were used directly without further
purification. Silica gel, Sorbent Technologies 32–63 mm was used
for flash column chromatography. [1]H-NMR, [13]C-NMR and
195Pt-NMR were obtained on an ARX-400 Avance Bruker
spectrometer. [15]N-NMR was obtained on an ARX-600 Avance
Bruker spectrometer. Chemical shifts (d) are given in ppm relative
to TMS or DSS unless otherwise indicated. For 195Pt-NMR,
K2PtCl4 was used as external standard. For [15]N-NMR,
[15]NH4Cl was used as external standard. MS (HRMS, ESI)
spectra for all synthesized compounds were obtained at the PSU
Bioanalytical Mass Spectrometry Facility on a ThermoElectron
LTQ-Orbitrap high resolution mass spectrometer with a dedicated
Accela HPLC system.
Synthesis of N[3]-(tert-Butoxycarbonyl)-1,2,3-propa-
netriamine, 1. The title compound was synthesized from 3-
amino-1,2-propanediol as described previously [22], in three steps
and in an overall yield of 73%. NMR and MS structural
characterization are in agreement with the published data.
Synthesis of N-(tert-Butoxycarbonyl)-1-aminomethyl-
1,2 ethylenediamine)dichloroplatinum(II), 2. Compound
2 was synthesized using a modified procedure reported previously
[23]. Briefly, under Ar atmosphere K2PtCl4 (1.1 g, 2.64 mmol)
was dissolved in 50 ml of DI water. The Boc-protected diamine 1
(0.5 g, 2.64 mmol) was dissolved in 10 ml of DI water and added
to the K2PtCl4 solution under Ar. The mixture was stirred at room
temperature for 24 h, after which a pale yellow solid formed. The
solid was filtered, washed with water (5650 ml), and dried under
vacuum (Yield 0.9 g 75%). NMR and MS structural character-
ization are in agreement with the published data.
Synthesis of (1-aminomethyl-1,2-ethylenediamine)di-
chloroplatinum(II) hydrochloride, 3. Compound 3, was
synthesized by a modified procedure reported previously [23].
Compound 2 (500 mg, 1.10 mmol) was suspended in 50 ml of
0.1M HCl, followed by the addition of 2.5 ml of 1M HCl. The
reaction mixture was heated at 50uC for 24 h, then 0.5 ml of 1M
HCl was added and the reaction mixture heated at 50uC for
additional 24 h. The mixture was allowed to cool down to room
temperature and filtered through a 0.22 mm syringe filter to
remove a white precipitate. The filtrate was evaporated under
vacuum and the yellow residue dried under vacuum (Yield
410 mg, 96%). NMR and MS structural characterization are in
agreement with the published data.
Synthesis of (1-aminomethyl-1,2-ethylenediamine)dia-
mineplatinum(II), 5. Compound 3 (200 mg, 0.512 mmol) was
suspended in 5 ml of Milli-Q type water, then the mixture was
heated and stirred at 40uC for 4 h. NH4OH (1.28 mmol) was
added in one portion and the reaction mixture heated at 40uC for
additional 2 h. The mixture was allowed to cool down to room
temperature, then additional NH4OH (1.28 mmol) was added and
the mixture allowed to stand for 3 h without stirring. The solvent
was evaporated under vacuum to leave a yellow residue (Yield
159.5 mg, 98%). [1]H NMR (400 MHz, D2O) d 2.64–2.74 (1H,
m), 3.02–3.12 (2H, m), 3.28–3.41 (2H, m). [13]C NMR
(101 MHz, D2O) d 48.76, 46.01, 38.68.
195Pt NMR (101 MHz,
D2O) d 22757.04, 22782.69. HR ESI MS, m/z [M]
+ 317.1058;
calc. for C3H17N5Pt, 317.1105; m/z [M]
2+ 158.5556; calc for
C3H17N5Pt; 158.5550, m/z [M-NH3]
+ 300.0790; calc. for
C3H17N5Pt, 301.0866; m/z [M-NH3]
2+ 150.5435, calc. for
C3H17N5Pt 150.5433.
Synthesis of 2ClPt-agarose and 2NH3Pt-agarose
conjugates
Each of the Pt complexes 3 and 5 was dissolved at 10 mg/ml in
0.1 M NaHCO3 (pH 8.3). 1 ml of the Pt complex solution was
added to 100 ml of Affi-Gel 10 (Bio-Rad, Hercules, CA). The
mixture was incubated at 4uC overnight. The residual active esters
on the gel were blocked with 1 M ethanolamine (pH 8.0) for 1 h.
The Pt-agarose conjugate was washed with cold 0.1 M NaHCO3
(pH 8.3) to remove unbound Pt complex.
Cell culture. The mouse organ of Corti HEI-OC1 and stria
vascularis SV-k1 cells have been previously described [24,25]
(generous gifts from Dr. Federico Kalinec, House Research
Institute), and were maintained at 33uC with 10% CO2 [26].
Mouse kidney proximal tubule KPT2 and KPT11, and distal
tubule KDT3 as previously described [26,27], hepatocyte AML12
(ATCC), embryonic fibroblast K41 [28], and human embryonic
kidney 293T cells (ATCC) were maintained at 37uC with 5%
CO2. All cells were maintained in growth medium (DMEM with
10% FBS).
Pt-agarose pull-down assay. Cells were lysed in buffer
containing 150 mM NaCl, 50 mM Tris, pH 7.5, 5 mM EDTA,
1% Triton X-100 with protease inhibitor cocktail (Sigma), and
centrifuged (14,000 g, 10 min) at 4uC to remove cell debris.
Protein concentration was adjusted to 2 mg/ml for all samples.
The Pt-agarose conjugate was incubated with whole cell extract
(1 ml) for 2 h at 4uC. Beads with bound proteins were spun down
by brief centrifugation, and washed with the same lysis buffer at
4uC. The proteins were removed from Pt-agarose in SDS sample
buffer, boiled for 2 min, and separated by protein gel electropho-
resis (8% gel) prior to Coomassie blue staining. For pull-down of
FLAG-tagged HSP90 proteins (FLAG-HSP90), 293T cells trans-
fected with FLAG-tagged HSP90a or HSP90b were lysed in lysis
buffer containing glycerol at 10% final concentration for cell lysate
preparation, and 50 ml Affi-Gel 10 and 500 ml of Pt complex
solution (5 mg Pt dissolved) were used to synthesize 2ClPt-agarose
or 2NH3Pt-agarose. After ethanolamine treatment, the beads were
further blocked with 5% bovine serum albumin (BSA)-containing
phosphate-buffered saline (PBS) for 3 h at 4uC, prior to adding cell
lysate 1 ml (400 mg/ml) for protein binding.
Mass spectrometry. Mass spectrometric analysis was per-
formed by the Proteomics Shared Resource facility at Oregon
Health & Science University. Briefly, Pt-binding protein bands
were excised from a Coomassie-stained gel, washed twice in
50 mM ammonium bicarbonate/50% (v/v) acetonitrile and dried.
The samples were reduced in 10 mM DTT/100 mM ammonium
bicarbonate, alkylated in 55 mM iodoacetamide/100 mM ammo-
nium bicarbonate, and dehydrated gels re-swelled in digestion
buffer containing 50 mM ammonium bicarbonate/5 mM CaCl2/
Figure. 1. Structures of cisplatin and carboplatin.
doi:10.1371/journal.pone.0066220.g001
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12.5 ng/ ml sequencing grade modified trypsin (Promega, Madi-
son, WI). Following an overnight incubation at 37uC, extracted
peptides were identified by collection of MS/MS data using a
Velos Pro linear ion trap mass spectrometer (ThermoFisher, San
Jose, CA). Peptides were separated using an Agilent 1100 series
capillary LC system (Agilent Technologies Inc, Santa Clara, CA)
and 0.56250 mm Zorbax SB-C18 column (Agilent Technologies).
Proteins were identified by collection of data-dependent MS/MS
spectra and using both Mascot (Matrix Science, London, UK) and
Sequest (ThermoFisher) was used to compare spectra to a mouse
only protein database (SwissProt, Swiss Institute of Bioinformatics,
downloaded on March 1st 2012) with trypsin specificity. The
database was also amended with an equal number of decoy
sequence-reversed entries to independently assess the protein false
discovery rate. Protein identification was then validated using the
program Scaffold (Proteome Software, Inc., Portland, OR) which
uses a probabilistic model to estimate the peptide and protein false
discovery rates [29,30], and the proteomic analysis workflow
(PAW) pipeline to maximize peptide identification while control-
ling both peptide and protein false discovery rates [31]. Minimum
peptide and protein probabilities were set at 80% and 99%,
respectively, with a minimum of 5 unique peptide matches per
protein. Using these criteria, there were no matches to the decoy
proteins with reversed sequences.
Plasmid constructs, transfection and retroviral
trunsduction. For FLAG-HSP90 expression constructs, rat
HSP90a and HSP90b cDNA from Open Biosystems (Clone ID
7114546 amd 7131767, respectively) were amplified by PCR with
primers 59-AAAGCGGCCGCGCCTGAGGAAACCCAGACC-
39 and 59-CCCGTCGACTAGTCTACTTCTTCCATG-39 for
HSP90a, and 59-AAAGCGGCCGCGCCTGAGGAAGTG-
CACCATG-39 and 59-CCCGTCGACTAATCCACTTCTTC-
CATG-39 for HSP90b, digested with NotI/SalI, and subcloned
into pFLAG-CMV2 vector. The resultant plasmids were trans-
fected into 293T cells using Lipofectamine 2000 (Invitrogen). For
the plasmid to generate stable cell lines that express HSP90a,
primers 59-AAATACGTACCGCCATGCCTGAGGAAACC-
CAGACC-39 and 59-CCCGTCGACTAGTCTACTTCTTC-
CATG-39 were used to amplify HSP90a by PCR, and the PCR
product was digested by SnaBI/SalI and subcloned into pBabe-
puro vector. The resultant plasmid was transfected into Phoenix
Eco packaging cell using Lipofectamine 2000. After 48 h, the
retrovirus-containing medium was collected, diluted (1:500) with
growth medium and added to KPT2 cells in culture. Growth
medium was changed again after 24 h and puromycin was added
at 2.5 mg/ml to select for retrovirus-infected cells. From dozens of
surviving cells after several days of puromycin treatment, several
clones were selected and expanded.
Western blotting. Proteins in lysis buffer were mixed with
SDS sample buffer, resolved in SDS-polyacrylamide gel, and
transferred to polyvinylidene fluoride membrane. After blocking
with 5% skim milk in Tris-buffered saline (TBS), HSP90a rabbit
polyclonal antibody (Lab Vision Cat #RB-119), HSP90b rabbit
polyclonal antibody (Lab Vision Cat #RB-118), FLAG mouse
monoclonal antibody (M2, Sigma), or actin rabbit polyclonal
antibody (Sigma, Cat #A2103) was incubated overnight at 4uC.
After horseradish peroxidase conjugated secondary antibody
incubation for 1 h, chemiluminescence with SuperSignal West
Dura Extended Duration Substrate (Pierce) was used to detect
protein expression.
MTT assay. Cell growth and viability were determined by
the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT), an indicator of mitochondrial dehydroge-
nase activity. Cells were plated at 3000 cells per well in a 96-well
plate. After incubation overnight to allow cells to attach to the
plate, cells were treated with cisplatin in culture medium for 2
days. 20 ml of 5 mg/ml MTT solution was added to each well, and
incubated for 4 h at 37uC, 5% CO2. Culture medium was then
replaced with 200 ml dimethyl sulfoxide (DMSO) in each well and
the optical density recorded at 540 nm with background
subtraction at 660 nm. Student’s t-test was used for statistical
analysis.
Results
Synthesis of Pt complexes bearing a free amino group for
conjugation to agarose
Two Pt-complex-agarose conjugates were synthesized and
designated as 2ClPt-agarose and 2NH3Pt-agarose. The corre-
sponding (1-aminomethyl-1,2-ethylenediamine)dichloroplatinu-
m(II) hydrochloride (complex 3) and (1-aminomethyl-1,2-ethyle-
nediamine)diamineplatinum(II) (complex 5), bearing an amino
group for conjugation to agarose were synthesized as shown in
Fig. 2. Complex 3 was synthesized in 52% overall yield by
following modified literature procedures [22,23]. The Pt complex
5 was obtained in 98% yield from 3, via the formation of the di-
aquo complex 4, followed by ligand exchange with an excess of
NH4OH [32,33]. Structural characterization of Pt complexes 3
and 5 was performed by NMR and MS. [1]H NMR (Fig. 3) shows
that there is a significant shift for the methylene and methine
protons of 5 as compared to those of 3; in addition the 195Pt NMR
spectra (Fig. 4) shows that the Pt complex 5 exhibits the expected
upfield chemical shift (22757.04, 22782.69 ppm) as compared to
that of 3, (22333.72 ppm) as a result of the ClRNH3 ligand
exchange. The upfield chemical shift observed for compound 5 is
also in agreement with the d (195Pt) value reported for the analog
cis-[Pt(ethylendiamine)(NH3)2]Cl2 at 22795 ppm [34]. In order to
further confirm the ClRNH3 ligand exchange, a [15]N-labeled Pt
complex was also synthesized using labeled [15]NH4OH. [1]H
NMR and 195Pt NMR spectra of both non-labeled and [15]N-
labeled Pt complexes 5 exhibited similar chemical shifts and
splitting patterns (Figs. 3 and 4). In addition, [15]N-HIG and
[15]N-H HSQC NMR experiments suggest that at least one
[15]NH3 is coordinated to the Pt atom since a peak with a
complex splitting pattern is observed at 247.2 ppm (data not
shown). The HR ESI positive mode mass spectrum (Fig. 5) of
compound 5 shows the characteristic isotopic pattern of Pt for the
parent ion m/z calculated for [M]+ C3H17N5Pt; 317.1105; m/z
observed; 317.1058 and for its corresponding [M]2+ ion; m/z
calculated for C3H17N5Pt; 158.5550; m/z observed; 158.5556. A
second signal of same intensity as for the [M]2+ ion could be
assigned as the [M-NH3]
2+ fragment; m/z calculated for
C3H14N4Pt; 150.5433 m/z observed; 150.5435, this could be
associated to the peak observed with a m/z of 300.0790; calculated
for [M-NH3]
+ 301.0866.
2NH3Pt-agarose binds to proteins with higher affinity
compared to 2ClPt-agarose
We conjugated Pt complexes 3 and 5 to agarose to produce the
corresponding 2ClPt-agarose and 2NH3Pt-agarose conjugates.
These conjugates were used to perform protein pull-down assays
using total cell lysate from mouse organ of Corti HEI-OC1 cells,
similar to that described previous for gentamicin-binding proteins
[26,28]. The bound protein samples were removed from Pt-
agarose and analyzed by SDS-gel electrophoresis and Coomassie
blue staining. Many protein bands, including several intense
bands, were detected in the sample from 2NH3Pt-agarose, while
Identification of Cisplatin-Binding Proteins
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fewer, less intense bands were detected in the sample from 2ClPt-
agarose (Fig. 6A).
Identification of cisplatin-binding proteins
Using the 2NH3Pt-agarose, we pulled down proteins from cell
lysate of several different mouse cell lines. Because of our interest
in ototoxicity and nephrotoxicity induced by cisplatin, we used two
cochlear cell lines (HEI-OC1 and SV-k1), and two kidney cell lines
(KPT11 and KDT3). We also used murine AML12 cells (liver
hepatocytes) and K41 cells (mouse embryonic fibroblasts). As
shown in Fig. 6B, all binding protein samples exhibited similar
band patterns, although some differences in band intensity
patterns could be detected among different cell lines, including a
strong band around 200 kDa (myosin IIA) in only HEI-OC1 cells
and a band around 85 kDa (HSP90a/b) that is much weaker in
KPT11 (Fig. 6B). The band around 55 kDa (tubulin) was also low
intensity in kidney cells compared to the other cells. We excised
protein bands with high intensities from the HEI-OC1 sample and
analyzed each band by mass spectrometry, because these bands
are likely specific binding proteins to cisplatin’s amino groups, and
Figure. 2. Synthesis of Pt complexes 3 and 5.
doi:10.1371/journal.pone.0066220.g002
Figure. 3. [1]H NMR of Pt complexes. [1]H NMR spectra in D2O shows methylene and methine proton shifts in complex 5 as compared to that of
3. [15]N-labeled (top) and non-labeled (middle) complex 5 exhibit similar chemical shifts and splitting patterns.
doi:10.1371/journal.pone.0066220.g003
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Figure. 4. 195PtNMR spectra of complexes 3 and 5 in D2O. Pt complex 5 shows an upfield chemical shift as compared to that of 3. Similar
chemical shifts are observed for the [15]N-labeled (top) and non-labeled (middle) complex 5.
doi:10.1371/journal.pone.0066220.g004
Figure. 5. HR ESI positive mode MS spectrum of complex 5.
doi:10.1371/journal.pone.0066220.g005
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these same bands were weak or non-existent in pull-down samples
from 2ClPt-agarose or agarose alone. The most abundant proteins
identified were non-muscle myosin IIA, glucose-regulated protein
of 94 kDa (GRP94), valosin-containing protein (VCP), heat shock
protein 90a and b (HSP90a/b), calreticulin, tubulin (seven
isoforms: a1a, b2a, b2b, b3, b4b, b5, and b6), and 60S ribosomal
protein L5. Additional gel band analysis by mass spectrometry
identified several more proteins (a, b, c, d, and e in Fig. 6B), and
the mass spectrometry results are shown in Table 1. The histidine
content in each identified protein is also included in Table 1, since
recent reports suggest that histidine residues in a protein
contribute to cisplatin binding [35,36]. While most of the proteins
have low histidine contents, higher levels in casein kinase II and
eukaryotic translation initiation factor 3 may contribute to binding
of these proteins to cisplatin.
HSP90a expression is low in kidney proximal tubule cells
Since the 85 kDa band shown in Fig. 6B was weak in KPT11
cells, we wanted to determine which of HSP90a and HSP90b that
was low in expression in these cells. Western blotting analysis on
total cell lysate revealed that HSP90a protein expression was very
low in KPT11 cells compared to the other cell lines, although
HSP90b expression was also relatively low (Fig. 7A), To determine
if the binding affinity for cisplatin was different between HSP90a
and HSP90b, Pt-agarose pull-down assay was performed using cell
lysate from 293T cells transfected with FLAG-HSP90a and -
HSP90b, and analyzed by Western blotting. 2NH3Pt-agarose
pulled down both FLAG-tagged HSP90 proteins at similar
amounts, which suggests that there was no significant difference
in binding affinity for cisplatin. 2ClPt-agarose also pulled down
these proteins, but at levels nearly as low as agarose without Pt,
suggesting that HSP90 binding to 2ClPt-agarose is likely non-
specific.
HSP90a expression contributes to cisplatin-induced
cytotoxicity
As a first step to determine if HSP90a has a role in cisplatin-
induced cytotoxicity, we compared mouse kidney cell lines for
sensitivity to cisplatin treatment. As expected from kidney
proximal tubule as a major cisplatin toxicity site, proximal tubule
KPT11 and KPT2 cells showed lower cell viability compared to
distal tubule KDT3 after 2 days of cisplatin treatment (Fig. 8A).
To determine how HSP90a expression affects cisplatin-induced
cytotoxicity, we attempted to use RNA interference and knocked
down HSP90a expression in KDT3; this resulted in the death of
most cells transfected with HSP90a siRNA, even without cisplatin
treatment (unpublished data). Therefore, we used an alternative
approach, and generated stable cell lines derived from KPT2 cells
with higher expression levels of HSP90a (KPT2-HSP90a) by
retroviral gene transfer. Western blotting confirmed that these
KPT2-HSP90a cells express higher levels of HSP90a, compared
to parental KPT2 and KPT2 with empty pBabe vector control
(KPT2-pBabe) cell lines (Fig. 8B). The KPT2-HSP90a cells
(HSP90a#1 and #2) exhibited faster cellular growth compared to
KPT2-pBabe cell lines (pBabe#1 and #2), as assessed by MTT
assay (Fig. 8C). Strikingly, cisplatin treatment on these cell lines for
2 days revealed that KPT2-HSP90a cells were more sensitive to
cisplatin compared to KPT2-pBabe cells, suggesting that HSP90a
expression contributes to cisplatin cytotoxicity.
Discussion
Although cisplatin-DNA adduct formation and subsequent
apoptosis mechanisms in cancer have been well documented, its
toxicity mechanisms in the cochlea and kidney are not well
understood. Oxidative stress induced by aquated cisplatin likely
causes ototoxicity and nephrotoxicity. However, aquation of
carboplatin is much slower than cisplatin, yet this drug is still
toxic to the cochlea and kidney. We hypothesized that cochlear-
and kidney-specific proteins bind to cisplatin and carboplatin at
the two amino groups, and that this drug-protein interaction
induces cytotoxicity. To identify such proteins, we decided to use
the drug-agarose conjugation technique that we used previously to
identify gentamicin-binding proteins [26,28]. This method took
advantage of existing cell lines generated from mouse cochlea or
kidney tissue, to avoid problems with very limited amounts of
tissues available from each animal, and the extended time needed
to extract proteins from in vivo tissues that can be a major cause of
protein degradation. Since the amino groups of cisplatin are -NH3
covalently coordinated to the platinum atom, these amino groups
Figure. 6. Cisplatin-binding protein pull-down assay results. (A)
Pull-down assay samples using HEI-OC1 cells. Agarose without Pt
conjugation (No Pt) was used as a control. 2NH3Pt-agarose pulled down
several proteins in significant amounts, while 2ClPt-agarose only pulled
down fewer proteins in lower amounts. The total cell lysate (Lysate)
sample before pull-down is to show relative expression levels of
proteins with different molecular mass. (B) 2NH3Pt-agarose pull-down
assay results. Several protein bands with high intensity appeared in all
cells tested, with some minor band differences in different lanes. Gel
bands were excised from HEI-OC1 samples and analyzed by mass
spectrometry. Protein names identified in gel regions a, b, c, d and e are
shown in Table 1.
doi:10.1371/journal.pone.0066220.g006
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cannot be used for conjugation to agarose. In addition,
conjugation of agarose to a covalently coordinated amino group
of cisplatin would make proteins inaccessible to cisplatin at this
site. Therefore, we synthesized platinum complexes that contain
another free amino group for conjugation to agarose.
Pull-down assays using Pt-agarose conjugates revealed that the
amino group site of cisplatin has much higher affinities for protein
binding compared to the chloride site. Although aquated cisplatin
binds to antioxidant proteins at the chloride site, it is likely these
proteins are not abundantly expressed in the cell lines tested,
because we only detected several weak protein bands by SDS-gel
analysis. Unlike the chloride site of cisplatin which is the binding
site for DNA and antioxidants [7,14], the role of the amino group
site has been unknown. It is, therefore, significant that we
identified several binding proteins to the amino group site which
may influence the efficacy of cisplatin-induced toxicity.
In the 2NH3Pt-agarose pull down samples, we expected to see
some differences among cell lines in Coomassie blue-stained
protein bands. Specifically, we expected more proteins in HEI-
OC1 and KPT11 samples compared to the others because
cochlear hair cells and kidney proximal tubule cells are major sites
of cisplatin-induced toxicity in these organs. However, we did not
find significant differences among the mouse cell lines we tested. It
is possible that these cell lines have gained some common
characteristics that the original tissues do not. Gene expression
associated with rapid cellular proliferation likely is a major factor.
We will discuss several of the most abundant proteins that bound
to 2NH3Pt-agarose and their relevance to cisplatin-induced
cytotoxicity and/or tumor resistance to cisplatin treatment.
Myosin IIA
Myosin IIA, also known as myosin-9, is an isoform of class II
non-muscle myosins. Myosin IIA regulates cell motility and
maintains a balance between actomyosin and microtubule systems
Table 1. Cisplatin-binding proteins identified in excised gel bands.
Protein name (gene name) [gel region]
Protein
MW
Unique
peptides
Unique
spectra
Total
spectra
Sequence
coverage (%)
Histidine
content (%)
Myosin-9 (Myh9) 226373 203 706 833 78.0 1.43
*Endoplasmin (Hsp90b1) 92477 74 346 361 69.2 1.25
**Transitional endoplasmic reticulum ATPase (Vcp) 89323 72 317 326 77.0 1.24
Heat shock protein HSP 90-alpha (Hsp90aa1) 84789 69 276 490 63.2 1.64
Heat shock protein HSP 90-beta (Hsp90ab1) 83282 42 254 531 66.6 1.80
Calreticulin (Calr) 47996 36 314 314 70.2 1.68
60S ribosomal protein L5 (Rpl5) 34402 36 223 223 68.7 1.68
Protein disulfide-isomerase A4 (Pdia4) [a] 71983 48 251 251 61.0 1.87
78 kDa glucose-regulated protein (Hspa5) [a] 72423 45 162 176 57.4 0.92
Elongation factor 1-gamma (Eef1g) [b] 50062 27 94 94 51.3 1.83
Elongation factor 1-alpha (Eef1a1) [b] 50115 24 63 63 49.6 2.16
Lupus La protein homolog (Ssb) [c] 47757 37 99 99 59.8 2.65
Obg-like ATPase 1 (Ola1) [c] 44731 33 128 128 73.0 2.27
COP9 signalosome complex subunit 4 (Cops4) [d] 46286 29 71 71 82.3 2.71
Casein kinase II subunit alpha (Csnk2a1) [d] 45135 22 62 66 58.1 4.09
Nucleophosmin (Npm1) [e] 32561 25 80 80 70.5 1.71
Eukaryotic translation initiation factor 3 subunit I (Eif3i) [e] 36462 21 81 81 80.6 3.38
Protein and gene names are those used in the SwissProt database. Gel regions of the identified proteins are indicated in Fig. 6B. ‘‘Protein MW’’ is the molecular weight of
the protein sequence from the SwissProt database. ‘‘Total spectra’’ is the number of MS/MS spectra matched to the protein sequence. ‘‘Unique spectra’’ is the number
of MS/MS spectra that are not shared between other protein sequences in the database. ‘‘Unique peptides’’ is the number of different amino acid sequences matched.
‘‘Sequence coverage’’ is the percentage of the total protein sequence matched to assigned MS/MS spectra. ‘‘Histidine content’’ is the percentage of the histidine
residues in the total amino acids of each protein. Myosin-9 is the same as myosin IIA. *Endoplasmin is the same as GRP94. **Transitional endoplasmic reticulum ATPase
is the same as VCP. The seven identified isoforms of tubulin are not included in the table.
doi:10.1371/journal.pone.0066220.t001
Figure. 7. Protein expression and cisplatin-binding of HSP90a
and HSP90b. (A) HSP90 protein expression analysis. Total cell lysates
from cell lines used for pull-down assay were analyzed by Western
blotting, using antibodies for HSP90a and HSP90b. KPT11 cell sample
showed very low expression of HSP90a. (B) Pt-agarose pull-down assay
using 293T cells transfected with FLAG-HSP90a or -HSP90b. 2NH3Pt-
agarose pulled down the two HSP90 isoforms with similar amounts.
doi:10.1371/journal.pone.0066220.g007
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[37]. In the cochlea, this protein is expressed in sensory hair cells
and its mutation is responsible for syndromic and nonsyndromic
hearing loss [38,39]. Although exact functions of myosin IIA in
hair cells are unclear, localization of this protein within the
mitochondria suggests that it has an important role in maintaining
mitochondrial function of hair cells [40].
GRP94
Glucose-regulated protein 94 (GRP94), also known as endo-
plasmin or HSP90B1, is a chaperone protein in the endoplasmic
reticulum (ER). This is the most abundant protein in the ER,
accounting for 5–10% of all the lumenal proteins [41]. However,
its function is not as well-defined as most other ER-localized
proteins. Unlike many other molecular chaperones in the ER,
GRP94 interacts with a limited set of protein substrates. GRP94
binds to only several different proteins in the secretory pathway,
including Ig chains, MHC class II, thyroglobulin, erbB2, a herpes
virus glycoprotein, and apolipoprotein B [42]. GRP94 can also
bind to peptides, giving rise to GRP94’s potential as a cancer
vaccine to induce a T cell response [42]. Physiological functions of
GRP94 in the ER are thought to be similar to its cytosolic
counterpart HSP90.
HSP90
Heat shock protein 90 (HSP90) is a cytoplasmic molecular
chaperone. The a form is inducible and b form is constitutively
expressed, and these isoforms are highly similar in sequence and
function. HSP90 is generally thought to function in assisting
protein folding and maintenance, and degradation of misfolded
proteins. Recent advances in cancer biology have revealed critical
roles of HSP90 in cancer cells, where HSP90 protects mutated and
overexpressed proteins encoded by oncogenes from degradation,
facilitating cancer cell survival [43].
Figure. 8. HSP90a expression and cell viability. (A) MTT assay on cells treated with cisplatin for 2 days showed that kidney proximal tubule cells
(KPT11 and KPT2) had lower viability compared to kidney distal tubule KDT3 cells (**P,0.01 between either one of proximal tubule cell lines and
KDT3). (B) Western blotting confirmed that KPT2-HSP90a cell lines (HSP90a#1 and#2) express higher levels of HSP90a compared to parental KPT2 or
KPT2 with empty pBabe vector control. (C) Cellular growth for 2 days was assessed by MTT assay, and KPT2-HSP90a cell lines showed faster cellular
growth compared to KPT2-pBabe cell lines (**P,0.01). (D) Cisplatin treatment for 2 days showed that KPT2-HSP90a cell lines had lower viability
compared to KPT2-pBabe cell lines (**P,0.01 between either one of KPT2-HSP90a and either one of KPT2-pBabe).
doi:10.1371/journal.pone.0066220.g008
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HSP90 has previously been identified as a cisplatin-binding
protein [44]. In this study, we expected that HSP90 was protective
against cisplatin treatment, and that kidney proximal tubule cells
were sensitive to cisplatin toxicity because of low expression of
HSP90. However, cell viability experiments using kidney proximal
tubule cell lines with exogenous HSP90a expression suggested that
HSP90a expression contributes to cisplatin-induced cytotoxicity.
Based on the accelerated cellular growth in these cell lines, this
raises a possibility that HSP90a-induced faster cellular growth is
the major cause of enhanced sensitivity to cisplatin. Perhaps in
some cancer cells, overexpression of HSP90a makes these cells
more susceptible to cisplatin treatment. This possibility needs to be
carefully examined further and differences between cancer and
normal cells should be taken into consideration. Although the
significance of cisplatin binding to HSP90 is still unclear, low
expression of HSP90a in kidney proximal tubule cells suggests that
HSP90 could be protective against cisplatin in vivo, where cells do
not rapidly proliferate. We also predict that HSP90 is protective
against cisplatin-induced ototoxicity, since heat shock proteins
including HSP32 have been shown to inhibit ototoxicity [45]. In
support of this possibility, cisplatin binding to HSP90 reduces its
chaperone activity, which would further decrease cellular viability,
causing nephrotoxicity [46].
Calreticulin
Calreticulin is an ER-localized protein that specifically binds to
glycoproteins. This is also a molecular chaperone assisting in
protein folding and trafficking misfolded proteins for degradation
[47]. Identification of calreticulin as a cisplatin-binding protein has
potential significance, because calreticulin is also a gentamicin-
binding protein, and reduces gentamicin-induced cytotoxicity
[28,48]. Since both cisplatin and gentamicin induce toxicity in the
cochlea and kidney and calreticulin is expressed in these tissues
[28], the function of the protein may be highly relevant to
cisplatin-induced toxicity in these tissues.
GRP78
We identified glucose-regulated protein 78 (GRP78), also
known as BiP or HSPA5, with relatively low abundance. This
protein also functions as a molecular chaperone in the ER, like
GRP94 and calreticulin, and GRP78 expression levels have been
correlated with cisplatin resistance in certain cancers [49,50].
Overexpression and/or cisplatin-induced up-regulation of GRP78
significantly reduce the antineoplastic efficacy of cisplatin. Unlike
GRP94, this protein binds to a wide range of proteins and is
referred to as the master regulator of the ER [47].
VCP
Valosin-containing protein (VCP), also known as p97 or
transitional endoplasmic reticulum ATPase, is an ATPase of the
AAA family (ATPases associated with diverse cellular activities),
and is a key player in various ubiquitin-dependent processes [51].
VCP expression has also been correlated with cancers, including
non-small cell lung carcinoma and hepatocellular carcinoma
[52,53]. Significantly, VCP has been shown to promote tumor
suppressor protein 53BP1 recruitment to DNA damage sites to
repair the damage, providing defense against cancer for normal
cells [54].
Ribosomal protein L5
Ribosomes consist of a small 40S subunit and a large 60S
subunit. We identified L5, a part of the 60S subunit, to be a
cisplatin-binding protein. Although the role of this protein in
cancer is highly speculative, overexpression of ribosomal protein
L5 has been identified in several colorectal cancer cases [55],
which suggests a potential significance of the protein in tumor
development or resistance to antineoplastic drugs.
Conclusions
We synthesized agarose conjugates of two different platinum
complexes and performed pull-down assays to identify cisplatin-
binding proteins. While most of the proteins we identified were not
specific to the cochlea or kidney, we found that these cisplatin-
binding proteins to be highly relevant to cisplatin-induced
cytotoxicity. Some of these proteins likely contribute to cisplatin
sensitivity (e.g. HSP90) or resistance (e.g. GRP78) of cancers by
binding to cisplatin. The proteins identified here by this technique
could represent a minority of highly expressed proteins and not the
large number of proteins which are likely more poorly expressed.
Nevertheless, this study provides a method to identify novel
cisplatin-binding proteins and determine how their dysregulation
can contribute to cisplatin-induced toxicity as well as sensitivity or
resistance of tumor cells to cisplatin.
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